全骨髓和淋巴照射作为单倍体移植预处理联合移植后环磷酰胺
这项1期试验纳入31例高危和/或活动性原发难治性白血病或骨髓增生异常综合征患者,接受全骨髓和淋巴照射(TMLI)联合氟达拉滨、环磷酰胺预处理及移植后环磷酰胺(PTCy)单倍体造血细胞移植。TMLI剂量按200 cGy递增(1200-2000 cGy)。结论为该方案在高危人群中安全可行,结局令人期待。
要点
- 31例高危/活动性难治白血病或MDS接受TMLI联合PTCy单倍体移植,剂量1200-2000 cGy。
- 1例1800 cGy患者出现3级肺毒性(剂量限制性毒性)。
- 2000 cGy组1年复发/进展17%、无进展生存74%、总生存83%。
核心结论
- 在高危患者人群中,TMLI联合PTCy的单倍体造血细胞移植安全可行,结局令人期待。
研究设计与样本
- 1期试验,31例高危和/或活动性原发难治性白血病或骨髓增生异常综合征患者接受外周血干细胞单倍体造血细胞移植。
- 预处理方案为TMLI、氟达拉滨和环磷酰胺,TMLI剂量按200 cGy递增(1200-2000 cGy)。
- GVHD预防为PTCy联合他克莫司/吗替麦考酚酯。
主要发现
- 按Bearman量表,2级毒性包括黏膜炎(n=1)、肝脏(n=3)、胃肠道(n=5)和心脏(n=2)。
- 1例1800 cGy患者发生3级肺毒性(剂量限制性毒性)。
- 全队列随访23.9个月,2年非复发死亡率为13%。
- 100天2-4级和3-4级急性GVHD累积发生率分别为52%和6%,2年慢性GVHD为35%。
- 2000 cGy组中位随访12.3个月,1年复发/进展、无进展生存和总生存率分别为17%、74%和83%。
关键数值与推荐
- TMLI剂量递增范围为1200-2000 cGy,按200 cGy递增。
- GVHD预防为PTCy联合他克莫司/吗替麦考酚酯。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Posttransplant cyclophosphamide (PTCy) platform has shown low rates of graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) after haploidentical hematopoietic cell transplantation (HaploHCT). However, because of the limited disease control, relapse rate remains a major cause of treatment failure in high-risk patients. Total marrow and lymphoid irradiation (TMLI) allows for delivery of high radiation to bone marrow and other targeted structures, without increasing off-target radiation exposure and toxicity to end organs. In this phase 1 trial, 31 patients with high-risk and/or active primary refractory leukemias or myelodysplastic syndrome underwent peripheral blood stem cell HaploHCT with TMLI, fludarabine, and cyclophosphamide as the conditioning regimen. Radiation dose was escalated in increments of 200 cGy (1200-2000 cGy). GVHD prophylaxis was PTCy with tacrolimus/mycophenolate mofetil. Grade 2 toxicities by the Bearman scale were mucositis (n = 1), hepatic (n = 3), gastrointestinal (n = 5), and cardiac (n = 2). One patient (1800 cGy) experienced grade 3 pulmonary toxicity (dose-limiting toxicity). At a follow-up duration of 23.9 months for the whole cohort; 2-year NRM was 13%. Cumulative incidence of day 100 grade 2 to 4 and 3 to 4 acute GVHD was 52% and 6%, respectively. Chronic GVHD at 2 years was 35%. For patients treated with 2000 cGy, with a median follow-up duration of 12.3 months, 1-year relapse/progression, progression-free survival, and overall survival rates were 17%, 74%, and 83%, respectively. In conclusion, HaploHCT-TMLI with PTCy was safe and feasible in our high-risk patient population with promising outcomes.
引用
- Al Malki MM, Palmer J, Tsai NC, et al. Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Adv. 2022. PMID: 35838754. doi:10.1182/bloodadvances.2022007264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。